Previous 10 | Next 10 |
eFFECTOR Therapeutics ( NASDAQ: EFTR ) on Wednesday said it had dosed the first patient in the second cohort of its phase 1b clinical trial of its investigational cancer therapy zotatifin for the potential treatment of COVID-19. The early-stage trial is assessing the ...
- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 - - Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation - SAN DIEGO and REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE...
SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetin...
eFFECTOR Therapeutics press release ( NASDAQ: EFTR ): Q2 GAAP EPS of -$0.17. Grant Revenue of $2.01M (+191.3% Y/Y). The company had cash and cash equivalents, and short-term investments totaling $41.0 million as of June 30, 2022, compared to $45.7 million in cash and c...
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer SAN DIEGO and REDWOOD CITY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NAS...
SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Douglas Warner, M...
SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will p...
Shares of eFFECTOR Therapeutics (NASDAQ:EFTR) are down 22% in Monday afternoon trading even though the company's released encouraging interim phase 1/2 safety results on zotatifin for solid tumors. The eIF4A inhibitor was generally well tolerated, led to suppression o...
Gainers: Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) ...
Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer patients with Cyclin D amplification Management and key opinion leaders to pre...
News, Short Squeeze, Breakout and More Instantly...
eFFECTOR Therapeutics Inc. Company Name:
EFTR Stock Symbol:
NASDAQ Market:
eFFECTOR Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 38.2% to $0.24 on volume of 498,894,705 shares Qualigen Therapeutics Inc. (QLGN) rose 59.5% to $0.28 on volume of 243,116,946 shares NVIDIA Corporation (NVDA) fell 1.9% to $125.83 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 109.0% to $0.3668 on volume of 102,385,159 shares Maxeon Solar Technologies Ltd. (MAXN) rose 4.3% to $0.181 on volume of 66,422,365 shares NVIDIA Corporation (NVDA) fell 1.3% to $126.58 on volume...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...